Israel Englander Clene Inc. Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.28 - $0.53 $9,714 - $18,387	-34,693 Reduced 63.13%	20,263 $8,000
Q4 2023 Feb 14, 2024	BUY	$0.26 - $0.55 $11,369 - $24,050	43,728 Added 389.45%	54,956 $16,000
Q2 2023 Aug 14, 2023	SELL	$0.78 - $1.22 $31,390 - $49,097	-40,244 Reduced 78.19%	11,228 $9,000
Q1 2023 May 15, 2023	SELL	$0.95 - $1.62 $62,381 - $106,377	-65,665 Reduced 56.06%	51,472 $58,000
Q4 2022 Feb 14, 2023	SELL	$0.92 - $40.2 $85,511 - $3.74 Million	-92,947 Reduced 44.24%	117,137 $117,000
Q3 2022 Nov 14, 2022	SELL	$0.33 - $73.0 $11,870 - $2.63 Million	-35,970 Reduced 14.62%	210,084 $588,000

230K

25K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $279M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.